The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during ...

Once-daily asundexian 50 mg, on top of antiplatelet therapy, reduced risk for recurrent ischemic stroke after a ...

Please provide your email address to receive an email when new articles are posted on . Moreover, patients prescribed apixaban also experienced a lower incidence of gastrointestinal bleeding or ...

The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

No significant difference seen in composite outcome of stroke, systemic embolism, new covert embolic stroke.

Only anticoagulant proven to show superior risk reductions versus warfarin in three important outcomes: stroke, major bleeding and all-cause death First approval in any market worldwide of ELIQUIS for ...

RARITAN, NJ, Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved XARELTO® to reduce the risk of stroke and systemic embolism in patients with ...

Bristol-Myers Squibb and Pfizer announced the results from its Phase 3 ARISTOTLE trial evaluating Eliquis (apixaban) for the prevention of stroke or systemic embolism in patients with atrial ...

At both 6 months and 12 months follow-up, the rivaroxaban group was found to have more of these events than the apixaban group. Credit: Getty Images. In patients with atrial fibrillation and valvular ...

Catheter-directed thrombolysis (CDT) is associated with a lower risk for death and major bleeding complications than systemic thrombolysis for patients with intermediate- or high-risk pulmonary ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it expanded its Phase III OCEANIC clinical development program for the investigational drug asundexian (BAY2433334) by initiating a third ...

New study shows a longer course of dual antithrombotic therapy may not be necessary for some patients with atrial ...